里昂发表报告指，复星医药(02196)上半年业绩逊市场及该行预期，当中第二季收入及盈利分别跌4%及26.3%至105亿元人民币及7.9亿元人民币。
该行指，虽然对公司的长远增长故事持正面看法，但是对短期的盈利前景较不乐观，将公司目标价由31.52港元下调33%至21.21港元，并将其评级由“买入”降至“跑赢大市”。
【券商聚焦】里昂削复星医药(02196)目标价33%至21.21港元 评级降至“跑赢大市”
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.